... BiTE Treatment Can Have Side EffectsLike other medications, BiTEs may cause adverse events (side effects). ...
... The FDA granted the drug accelerated approval due to its performance in clinical studies.Since then, the FDA has approved three new BiTES: Elranatamab-bccm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab (Talvey) Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
8 Refractory Myeloma Therapies: Know Your Treatment Options
... The FDA granted the drug accelerated approval due to its performance in clinical studies.Since then, the FDA has approved three new BiTES: Elranatamab-bccm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab (Talvey) Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
... Bispecific T-cell engagers (BiTEs) — Also known as bispecific antibodies, BiTEs are newer immunotherapies that link immune cells directly to myeloma cells so they can attack them more effectively. Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). ...
Can Multiple Myeloma Be Cured? Advances in Research and Survival
... Bispecific T-cell engagers (BiTEs) — Also known as bispecific antibodies, BiTEs are newer immunotherapies that link immune cells directly to myeloma cells so they can attack them more effectively. Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). ...
... BiTEs are a type of monoclonal antibody — laboratory-made proteins that work like the antibodies your body naturally uses to find and fight infections and cancer.BiTEs like teclistamab-cqyv target myeloma in two ways. One part of the bispecific antibody binds to BCMA on the myeloma cell, and the other part binds to a nearby T cell. ...
What Is BCMA-Targeted Immunotherapy? (VIDEO)
... BiTEs are a type of monoclonal antibody — laboratory-made proteins that work like the antibodies your body naturally uses to find and fight infections and cancer.BiTEs like teclistamab-cqyv target myeloma in two ways. One part of the bispecific antibody binds to BCMA on the myeloma cell, and the other part binds to a nearby T cell. ...
... However, many targeted therapies can cause nausea and vomiting.Examples include proteasome inhibitors: Bortezomib (Velcade, Boruzu) Carfilzomib (Kyprolis) Ixazomib (Ninlaro) Other types of targeted drugs that may cause nausea include monoclonal antibodies, bispecific T-cell engagers (BiTEs) and nuclear export inhibitors, like selinexor (Xpovio).6. ...
Nausea With Multiple Myeloma: 6 Causes and 7 Tips To Feel Better
... However, many targeted therapies can cause nausea and vomiting.Examples include proteasome inhibitors: Bortezomib (Velcade, Boruzu) Carfilzomib (Kyprolis) Ixazomib (Ninlaro) Other types of targeted drugs that may cause nausea include monoclonal antibodies, bispecific T-cell engagers (BiTEs) and nuclear export inhibitors, like selinexor (Xpovio).6. ...
... Bispecific T-Cell EngagersBispecific T-cell engagers (BiTEs) are a newer approach to treating relapsed or refractory multiple myeloma that involves antibodies that can bind to two antigens at once. The FDA approved the BiTE teclistamab-cqyv (Tecvayli) in 2022 for treating people who had tried three prior lines of therapy. ...
Myeloma Relapse Rates and 9 Treatment Options for Relapses
... Bispecific T-Cell EngagersBispecific T-cell engagers (BiTEs) are a newer approach to treating relapsed or refractory multiple myeloma that involves antibodies that can bind to two antigens at once. The FDA approved the BiTE teclistamab-cqyv (Tecvayli) in 2022 for treating people who had tried three prior lines of therapy. ...
... Bispecific T-Cell EngagersBispecific T-cell engagers (BiTEs) are a newer approach to treating relapsed or refractory multiple myeloma that involves antibodies that can bind to two antigens at once. ...
12 Myeloma Treatment Options
... Bispecific T-Cell EngagersBispecific T-cell engagers (BiTEs) are a newer approach to treating relapsed or refractory multiple myeloma that involves antibodies that can bind to two antigens at once. ...
Join
